Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 14, 2020October 14, 2020

FDA Approves Use of Higher Palynziq Doses in Adults With PKU

News

The U.S. Food and Drug Administration (FDA) has agreed to increase the maximum Palynziq (pegvaliase-pqpz) dose allowed for treating adults with phenylketonuria (PKU), BioMarin announced. While the maximum dose previously ... Read more

September 9, 2020September 9, 2020

Amino Acid Supplement Improves Adherence to Medication in Adults With PKU, Study Finds

News

A slow-release formulation of large neutral amino acids (LNAAs) improves adherence to treatment and quality of life in adults with phenylketonuria (PKU), a study suggests. The study, “The Impact of a Slow-Release ... Read more

August 26, 2020August 26, 2020

Eye Exam May Help Assess PKU Severity, Study Suggests

News

The thickness of the retinal nerve fiber layer, or RNFL — a light-sensitive tissue layer of the eye — correlates with the levels of the amino acid phenylalanine and with cognitive ... Read more

May 13, 2020May 13, 2020

PTC Therapeutics Takes Over Clinical Development of CNSA-001

News

PTC Therapeutics will be advancing CNSA-001 (sepiapterin) — an investigational oral therapy for phenylketonuria (PKU) and other metabolic disorders — because the company is acquiring the original developer of the treatment, Censa Pharmaceuticals. ... Read more

March 12, 2020March 12, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking ... Read more